Takeda to Acquire URL Pharma for $800 Million - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Takeda to Acquire URL Pharma for $800 Million
Company makes bolt-on acquisition to enhance position in gout marketplace.


ePT--the Electronic Newsletter of Pharmaceutical Technology

Takeda Pharmaceutical has agreed to acquire URL Pharma for an upfront payment of $800 million and future performance-based, contingent, earn-out payments. The company announced the deal last week.

URL Pharma’s lead product is Colcrys (colchicine), a drug used to treat and prevent gout flares. Net sales for Colcrys in calendar year 2011 were more than $430 million, accounting for a major portion of URL’s 2011 revenues of $600 million. The drug complements Takeda’s position in the gout marketplace with Uloric (febuxostat), which is used to lower blood uric acid levels in adults with gout.

URL is headquartered in Philadelphia and has approximately 500 employees. In addition, URL Pharma has a contracted sales force consisting of approximately 350 individuals. The deal is expected to close in 60 days.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here